SCHEMBL22542846

SCHEMBL22542846

O=C(O)c1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccc(Br)cc23)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 5/20 0.74
▸ MEN1 O00255 6/20 0.70
▸ KMT2A Q03164 6/20 0.70
▸ LMNA P02545 3/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.64
▸ PTPN7 P35236 2/20 0.64
▸ DUSP3 P51452 2/20 0.64
▸ RXFP1 Q9HBX9 1/20 0.64
▸ MAPT P10636 8/20 0.63
▸ XBP1 P17861 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ CYP3A4 P08684 5/20 0.61
▸ POLB P06746 2/20 0.57
▸ CYP1A2 P05177 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ RECQL P46063 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22542971 0.89 KMT2A (0.81) CYP2C9MEN1KMT2ALMNANPSR1
SCHEMBL22542990 0.89 CYP2C9 (0.73) CYP2C9MEN1KMT2ALMNANPSR1
SCHEMBL22542789 0.87 CYP2C9 (0.74) CYP2C9MEN1KMT2APTPN7DUSP3
SCHEMBL22542788 0.87 ALDH1A1 (0.69) CYP2C9MEN1KMT2ALMNANPSR1
SCHEMBL7814193 0.82 GAA (0.71) CYP2C9MEN1KMT2ANPSR1RXFP1
SCHEMBL22543377 0.79 KMT2A (0.81) CYP2C9MEN1KMT2ALMNANPSR1
SCHEMBL22543110 0.76 CYP2C9 (0.77) CYP2C9MEN1KMT2ALMNANPSR1
SCHEMBL22543115 0.76 CYP2C9 (0.65) CYP2C9MEN1KMT2ALMNANPSR1
SCHEMBL22543372 0.76 ALDH1A1 (0.65) CYP2C9MEN1KMT2APTPN7DUSP3
SCHEMBL22543067 0.76 CYP2C9 (0.73) CYP2C9MEN1KMT2AMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200323960-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE BOISE STATE UNIVERSITY 2020-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200323960-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE OGFR, OGFRL1, ELAVL1 CYP2C9 4858/4885MEN1 1818/4885KMT2A 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback